Conclusions Retinal blood flow increases as a long-term effect of betaxolol and decreases as both a short-and long-term effects of timolol.
The intraocular pressure (IOP)-lowering effect of topical l3-adrenoceptor-blocking agents has been known for nearly 20 years. l ,2 Beta-blockers have become the treatment of choice for patients with elevated lOP and the early stages of glaucoma. More recently, investigators have begun to study the effects of l3-blocker therapy on visual field sensitivity in patients with glaucoma3-5 and ocular hypertension. 3, 4 In two separate studies, Flammer et al? compared the effects of 13-1 selective (betaxolol) with non- selective (timolol) l3-blocker treatment on lOP and the visual field. They found less visual field loss in betaxolol-treated patients than in timolol-treated patients, even though better lOP control was achieved with the latter. In a third study, Flammer et al. 3 found evidence that betaxolol might protect the visual field in patients with ocular hypertension. Similar findings were reported by Collignon-Brach 4 in patients with ocular hypertension and glaucoma, and by Kaiser et al. 5 in patients with glaucoma. These investigators concluded that factors other than lOP alone probably determine visual field outcome.
In light of those results, other investigators compared the effects of betaxolol with those of timolol on the ocular circulation in patients with primary open-angle glaucoma6 or normal tension glaucoma?·R In each study, betaxolol had a positive effect on various measures of ocular circulation compared with timolol.
The aim of the present study was to compare the effects of both a one-drop topical application and a twice-daily 2 week topical application of betaxolol and timolol on the retinal blood flow (RBF) in normal human subjects.
Materials and methods
Thirteen healthy men (aged 23-46 years; mean age 32 years) were recruited for this experiment. No participants had a history of systemic or intraocular disease, and none was taking topical or systemic medication during the time of the study. All eyes had a best corrected visual acuity of 20/20 or better, an lOP of less than 20 mmHg, and a normal anterior segment and fundus. Investigational review board approval was obtained for the study protocol, and written informed consent was obtained from each subject. All experimental procedures conformed to the tenets of the Declaration of Helsinki.
The pupils of both eyes of all subjects were dilated with 1% tropicamide. One drop of topical proparacaine HCl 0.5% was instilled in each eye and lOP was measured using Goldmann applanation tonometry. The axial length of each eye was measured by A-mode ultrasound (OcuScan, Alcon Surgical, Irvine, CA) to compute the intraocular light-scattering geometry for the laser Doppler measurements. An instant fundus photograph was taken of each eye (Nikon Retinapan 45II, Nikon, Tokyo, Japan) for selection and documentation of the laser Doppler measurement sites.
Subjects were seated for at least 5 min to establish steady-state measurements of heart rate (HR) and brachial artery blood pressure (BP) prior to laser Doppler testing.
A new retinal laser Doppler instrument recently described by Feke et a/.9 was used to measure the blood flow in a major temporal retinal vein in both eyes of each subject. In this fundus camera-like instrument, the retinal image is focused on the face of a CCD camera and can be viewed on a TV monitor. Eye tracking is performed by projecting a stripe from a green 543 nm HeNe laser through a beam-steering galvanometer system onto the retinal vein of interest. The stripe is oriented perpendicular to the axis of the vessel. The stripe reflected from the retina is incident on an array sensor that detects lateral motion of the vessel and controls the galvanometer system to stabilise the centre of the green tracking stripe on the centre of the vessel. The beam from a red 670 nm diode laser is the laser Doppler measuring source and is centred on the green stripe. Stabilisation of the centre of the stripe on the target vessel also results in stabilisation of the red measuring beam on the target vessel.
The red Doppler-shifted light scattered from the blood cells flowing in the retinal vein is detected simultaneously in two directions separated by a fixed angle. The signals from the two photomultiplier tube detectors undergo computer-controlled spectrum analysis, and sequential measurements of the centreline retinal blood speed (RBS) over a 2 s time interval are performed automatically. The diameter (D) of the retinal vein is determined automatically by computer analysis of the signal produced by the image of the vein on the array sensor. The cross-sectional area of the vein at the laser Doppler measurement site (area) is calculated assuming a circular cross-section. As previously described, lO RBF in the retinal vein is calculated as
Measurement of RBS and D were obtained at a single site along either a major superotemporal or inferotemporal retinal vein in both eyes of each subject. The same site was measured at baseline, and at 90 min and 2 weeks following treatment. Five measurements of RBS and D were obtained at each site. RBF was calculated from each set of measurements, and an average value was obtained.
In a double-masked randomised design following the baseline measurement of BP, HR, lOP, D, RBS and RBF, one eye of each subject received either one drop of betaxolol hydrochloride 0.5% (Betoptic, Alcon Japan, Tokyo) or one drop of 0.5% timolol maleate ophthalmic solution (Timoptol, Santen Pharmaceutical, Osaka, Japan). The fellow eye received one drop of placebo (physiological saline 0.9% NaCl). Ninety minutes later, the measurements were repeated. Subjects refrained from eating or drinking during the 90 min interval.
After completion of the 90 min measurements, subjects continued to be treated according to the previously described protocol with either betaxolol or timolol, i.e. one drop in one eye twice daily (8 o'clock in the morning and 8 o'clock in the evening) for 2 weeks. The fellow eye received one drop of placebo twice daily. At the end of 2 weeks, measurements were repeated at the same time of the day (2 o'clock in the afternoon) at which the 90 min measurement had been performed during the previous experiment.
Statistical analysis
Non-parametric Wilcoxon signed rank tests were used to analyse the statistical significance of changes from baseline of each measurement and to compare the percentage change of each measurement between eyes treated with either betaxolol, timolol or placebo.
Spearman rank correlation analysis was used to compare the percentage changes in perfusion pressure with the percentage changes in RBS and RBF. p values of less than 0.05 were considered to be statistically significant.
Results
Of the 13 subjects recruited, 7 received betaxolol and 6 received timolol. One subject who received timolol was excluded from the study when mild bilateral corneal erosion was observed at the time of the 90 min measurement. No treatment was necessary, and complete recovery of both corneas occurred after 1 day. Therefore, 12 subjects completed the study, 7 of whom were treated with betaxolol and 5 with timolol.
Changes in HR and mean BP, calculated as BP(diastole) + 1/3[BP(systole) -BP(diastole)], were analysed. Following administration of timolol, only the 90 min HR value was significantly lower than the baseline value (67 ± 5 beats/min vs 79 ± 7 min, respectively; p < 0.01). The HR value after 2 weeks of timolol treatment (73 ± 7 beats/min) was not significantly different from the baseline value. There were no statistically significant changes in mean BP in either experiment.
Summary of lOP results
The lOP levels measured at baseline, 90 min and 2 weeks following betaxolol treatment in both betaxolol-and placebo-treated eyes are shown in Table 1 . In betaxolol treated eyes, lOP decreased significantly compared with baseline values after both 90 min and 2 weeks (p = 0.02 and p = 0.03, respectively). lOP also decreased in the placebo-treated fellow eyes, but the decrease was not significant compared with baseline values after either 90 min or 2 weeks (p = 0.11 and p = 0.13, respectively). At 90 
Summary of laser Doppler velocimetry results
The RBF measurements at baseline, 90 min and 2 weeks following betaxolol treatment in both betaxolol-and placebo-treated fellow eyes are shown in Table 3 
I
There were no significant correlations between the changes in perfusion pressure, defined as 2/3 mean BP -lOP, and the changes in RBF in either betaxolol treated or timolol-treated eyes.
Discussion
The changes in lOP following both betaxolol and timolol treatments (Tables 1, 2 ) were similar to those previously reportedY-1 4 Gupta et aZY found a 28% decrease in lOP in betaxolol-treated eyes and a 13% decrease in placebo treated fellow eyes of patients with ocular hypertension 120 min after a one-drop application of topical betaxolol. Yoshida et al.12 found a 20% decrease in lOP in timolol- treated eyes and a 6% decrease in placebo-treated fellow eyes of normal subjects 90 min after a one-drop application of topical timolol. Grunwald13 found a 35% decrease in lOP in timolol-treated eyes and an 18% decrease in placebo-treated fellow eyes of normal subjects 90 min after a two-drop application of topical timolol. Grunwald 1 4 found a 38% decrease in lOP in timolol-treated eyes and a 22% decrease in placebo treated fellow eyes of patients with ocular hypertension 120 min after a one-drop application of topical timolol.
What is common to all of these studies is that lOP decreases not only in the drug-treated eyes but in the placebo-treated fellow eyes as well. Because of this crossover effect, differences in lOP between drug-treated eyes and placebo-treated fellow eyes may not be statistically significant. Whether the crossover effect results from the drugs acting via the central nervous system, or from a local effect of the drug reaching the fellow eye through the systemic circulation, is not known.
The changes in RBF measured following betaxolol treatment are also consistent with results previously published by Gupta et al.,
ll who reported that average RBF increased by 15% in patients with ocular hypertension 120 min after a one-drop application of topical betaxolol. The result was statistically significant (p = 0.03) and consistent with both the 6 ± 10% increase measured after 90 min and the 14 ± 9% increase measured after 2 weeks in the present study. To the best of our knowledge, no other studies of the effect of betaxolol on the human retinal circulation have been published. Regarding the effects of timolol, we12 previously reported that RBF decreased by 7 ± 17% in normal subjects 90 min after a one-drop application of topical timolol. Although that decrease was not statistically significant, it is consistent with the 18 ± 5% decrease measured after 90 min and the 14 ± 9% decrease after 2 weeks in the present study. On the other hand, Grunwald13,1 4 reported RBF increases in both normal subjects (13 ± 10%) and patients with ocular hypertension (8 ± 7%) after a one-drop application of topical timolol. Grunwald1s also reported an average 10% increase in RBF in normal subjects following 2 weeks of twice-daily timolol treatment. That result, however, was not statistically significant.
It is interesting to note that Martin and Rabineau16 reported that 1 week of twice-daily timolol treatment produced a statistically significant 4.1 % decrease in the diameters of the larger retinal arteries in normal subjects. It has been reported1 7 that blood flow in such vessels varies as arterial diameter to the power 4. Therefore, a 4.1 % decrease in arterial diameter would be associated with a 17% decrease in blood flow rate, which is consistent with the results we obtained in the present study.
The study of Van Buskirk et al. 18 also indicated differences between the haemodynamic effects of timolol and betaxolol. Single doses of either timolol or betaxolol produced substantial localised constriction of the arterioles that supply the ciliary processes in the rabbit eye. However, after 7 weeks of daily treatment, even though the initial vasoconstriction persisted in the timolol-treated eyes, it was no longer present in the betaxolol-treated eyes. The mechanism of action of timolol and betaxolol on retinal haemodynamics is most likely related to the I)-adrenoceptor-blocking activity of these agents. Investigators have used autoradiographic methods to show that is-receptors are present in human retinal blood vessels1 9 and the human anterior optic nerve and optic nerve head? O In these locations, most receptors identified were of the 1)-2 subtype. Because stimulation of the 1)-2 receptors in the vasculature elicits vasodilation, the antagonism of the endogenous state of vasodilation by the non-selective I)-blocking agent timolol would increase the vascular resistance to flow, and thus decrease the blood flow rate in the retinal vessels.
Because there are few is-I receptors in human retinal vessels, the selective is-I blocking agent betaxolol would have little effect on the endogenous state of vasodilation of retinal vessels and, thus, little or no effect on RBF.
The fact that betaxolol treatment actually increases RBF suggests that it has direct vascular-relaxing properties in addition to its 1)-1 blocking properties. Studies21-23 have demonstrated that the vascular relaxing property of betaxolol is the result of the inhibition of calcium ion influx across vascular smooth muscle cell membranes. In other words, the action of betaxolol resembles that of a calcium channel blocker such as verapamil. It is interesting to note that Netland et al. 2 4 recently showed that topical verapamil produced a statistically significant 10 ± 4% increase in optic nerve head capillary blood speed in normal subjects, an increase similar in magnitude to the increase in RBF following topical betaxolol measured in the present study. The long-term beneficial effects of betaxolol treatment on visual field outcome3-S may be related to the circulation-enhancing properties of the drug.
